Our Discoveries

Spatial heatmap of CD3+ T cells in small cell lung cancer (SCLC) tumors. Top: Notch1 gene inactive, “cold” SCLC with T cells located on the tumor periphery (immune-excluded). Bottom: Notch1 gene active, “hot” SCLC with abundant T cell tumor infiltration (immune-inflamed).

Activated gene elicits robust immune response in lung cancer

The activation of NOTCH1, a gene known to control cell differentiation and growth, stimulates a robust immune response in small cell lung cancer. Expression of this gene can also predict survival with immunotherapy.

Cells showing the biosensor used in this study to test the activity of APC/C

Study uncovers new details on pulsing enzyme activity during cell cycle

Enzymatic activity during the start of the cell cycle could be harnessed to inhibit cancer cell reproduction.

An illustration of immune cells with zeroes and ones, representing CIDE, a new, large-scale immuno-oncology data platform.

Cancer Immunology Data Engine uncovers secreted proteins with therapeutic potential

CCR researchers have developed a new tool that identifies secreted proteins associated with immunotherapy outcomes.

Graphic depiction of near-infrared photoimmunotherapy (NIR-PIT) targeted against ICAM-1 markers (small, blue, Y-shaped), causing cancer cell death and suppressed tumor growth (pink cluster, center).

CCR-developed cancer therapy shrinks tumors and boosts immune response

A targeted cancer therapy developed at CCR shows promise in its ability to target a common cancer cell marker, both shrinking tumors and producing a boosted immune response.

A graphic depiction of the dimethoxyphenyl cyanoacrylamide (DiMe) chemical warhead facilitating reversible binding of drug to its molecular target.

Synthesized chemical component helps cancer drugs remain stable in water

Researchers developed a new chemical component that can be attached to drug molecules to make them more stable in water without losing effectiveness. This innovation could improve the performance of some cancer treatments.

Combining bevacizumab with erlotinib shrinks tumors in patients with rare and aggressive kidney cancer

Seventy-two percent of patients with HLRCC-associated kidney cancers, for which there previously was no known drug treatment, responded to the therapy in a clinical trial.

Acute myeloid leukemia. Image credit: iStock

Researchers uncover why a leukemia treatment can cause problems with movement and balance

Ara-C, also known as cytarabine, is the most common chemotherapy to cause cerebellar toxicity. Researchers discovered how the treatment leaves certain neurons with double-strand breaks in their DNA.

Blood from wildtype mice (left) showing blast-like T-ALL cells with characteristic blue nuclear staining; blood from mice in which CHMP5 is deficient in thymocytes (right) showing no evidence of T-ALL cells in the blood.

Protein shown to promote transcription factors that support cancer genes in leukemia

CCR researchers have discovered that the CHMP5 protein promotes transcription factors that initiate and sustain the expression of cancer genes in T-cell acute lymphoblastic leukemia models.

In people with VHL disease, HIF protein complexes accumulate and promote tumor growth. By binding to HIF-2α (green portion of the HIF protein complex), belzutifan (purple hexagon) inhibits HIF’s tumor-promoting activity.

Belzutifan works steadily in people with VHL-associated tumors

In a recent clinical trial, belzutifan shows long-lasting benefits for patients with von Hippel-Lindau disease.

Phylogenetic tree of 94 viral strains corresponding to 153 viral peptides that are beneficial virus-related antigens. Colors in the circles indicate different virus classifications at the species (inner circle) and genus (outer circle) level.

Protein found on the common cold virus can activate anti-cancer immune response

Researchers found a viral protein that can activate certain immune cells to produce robust anti-cancer responses against liver cancer.

Breadcrumb